UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010812
Receipt number R000012080
Scientific Title A study of interferon beta/ ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.
Date of disclosure of the study information 2013/05/27
Last modified on 2018/09/21 09:48:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of interferon beta/ ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

Acronym

Interferon beta with/without ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

Scientific Title

A study of interferon beta/ ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

Scientific Title:Acronym

Interferon beta with/without ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

Region

Japan


Condition

Condition

Chronic hepatitis C patients and compensated cirrhosis patients

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To verify whether can be improved therapeutic effect by the combined use of non-activated vitamin D to IFN beta or IFN beta / RBV, for chronic hepatitis C and compensated cirrhosis patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Negative result of HCV RNA test at 24 weeks after therapy.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Food

Interventions/Control_1

Chronic hepatitis C with high viral load:
Vitamin D(2000IU/day)for 4 weeks, vitamin D, IFN-beta(6 MIU)and ribavirin(600-1000mg/day)for 48 weeks. Negative result of HCV RNA test at 12-36 weeks for 72 weeks treatment.
HCV serogroup 2 patients were treatment for 24 weeks.

Chronic hepatitis C with low viral load :retreatment patients:
Vitamin D(2000IU/day)for 4 weeks, vitamin D, IFN-beta(6 MIU) and ribavirin(600-1000mg/day)for 24 weeks.

Chronic hepatitis C with low viral load:naive patients:
Vitamin D(2000IU/day)for 4 weeks, vitamin D and IFN-beta(6 MIU) for 8-24 weeks.

Compensated cirrhosis patients:
Vitamin D(2000IU/day)for 4 weeks, vitamin D and IFN-beta(6 MIU) for 36 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Chronic hepatitis C and compensated cirrhosis patients with serogroup 1 and low viral load, with serogroup 2.

Key exclusion criteria

pregnant women and nursing mothers

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Satoshi Mochida

Organization

Saitama Medical University

Division name

Division of Gastroenterology and Hepatology ,internal Medicine

Zip code


Address

38,Morohongou,Moroyama-machi,Iruma-gun,Saitama,Japan

TEL

049-276-1111

Email

hirb@saitama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nobuaki Nakayama

Organization

Saitama Medical University

Division name

Division of Gastroenterology and Hepatology ,internal Medicine

Zip code


Address

38,Morohongou,Moroyama-machi,Iruma-gun,Saitama,Japan

TEL

049-276-1111

Homepage URL


Email

hirb@saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical University

Institute

Department

Personal name



Funding Source

Organization

Saitama Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 05 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 13 Day

Date of IRB


Anticipated trial start date

2013 Year 05 Month 13 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 05 Month 27 Day

Last modified on

2018 Year 09 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012080


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name